Executive record

Ernest J. Scheidemann, Jr.

Director at Aspire Biopharma Holdings, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:ernest-j-scheidemann-jrVersion: public-0As of: 2026-09-30

Not yet claimed12 published Claims5 sources
  • Director

Key Claims

Biography

Interim Chief Financial Officer during fiscal year ended December 31, 2024 (resigned February 25, 2025). Partner in Florida CFO Group since February 2024 and founding member of interim/fractional CFO firm. Over 25 years leading financial activities for start-ups, high growth, restructuring and turnaround situations.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Chief Financial Officer · Organization not publishedASBP 10-K executive officers
  2. 2026 to end not publishedExecutive title: Interim Chief Financial Officer · Organization not publishedFCHS 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ASBP 10-K executive officers

    sec filing · Source published: Mar 30, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Executive company: Executive at Aspire Biopharma Holdings, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 15, 2026

  2. FCHS 10-K executive officers

    sec filing · Source published: Mar 11, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at First Choice Healthcare Solutions, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Interim Chief Financial Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Ernest J. Scheidemann, Jr. is also linked to Florida CFO Group as Partner. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. ASBP DEF 14A director slate

    sec filing · Source published: Feb 24, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Feb 24, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Aspire Biopharma Holdings, Inc. · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Aspire Biopharma Holdings, Inc. · Claim reviewed: May 16, 2026